NCT04944888View on ClinicalTrials.gov

GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions
Solid TumorHematologic Malignancy
Interventions
DRUG

Eliglustat

Eliglustat will be given to enrolled patients at dose of 84mg daily (dose 1) , and then at dose of 84mg twice daily (dose 2).

DRUG

Immune checkpoint inhibitor

immune checkpoint inhibitor (physician decided).

Trial Locations (1)

Unknown

Department of Biotherapeutic, Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER